CTMX
HEALTHCARECytomX Therapeutics Inc
$4.13+0.05 (+1.23%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CTMX Today?
No stock-specific AI insight has been generated for CTMX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.91$8.21
$4.13
Fundamentals
Market Cap$899M
P/E Ratio—
EPS$-0.15
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-0.2%
Debt / Equity—
Trading
Volume2.6M
Avg Volume (10D)—
Shares Outstanding217.7M
CTMX News
20 articles- CytomX Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business UpdateYahoo Finance·May 7, 2026
- Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 30, 2026
- Small Cap or Megacap: Which Healthcare Stock Is Right for You?The Motley Fool·Apr 22, 2026
- CytomX Therapeutics, Inc. (CTMX) A Top Healthcare Penny Stock Amid Colorectal Cancer Treatment ProgressYahoo Finance·Apr 14, 2026
- Analysts Bullish on CytomX Therapeutics (CTMX) As CTMX Prices $250 Million OfferingYahoo Finance·Apr 12, 2026
- How The CytomX Therapeutics (CTMX) Story Is Shifting With New Colorectal Cancer DataYahoo Finance·Apr 10, 2026
- CytomX Therapeutics (CTMX) Making Progress on Key Metastatic Colorectal Cancer TreatmentYahoo Finance·Apr 6, 2026
- Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?Yahoo Finance·Apr 1, 2026
- CytomX Therapeutics (CTMX) Gains Analyst Confidence on Trial ProgressYahoo Finance·Mar 27, 2026
- How The CytomX Therapeutics (CTMX) Narrative Is Shifting With New Colorectal Cancer DataYahoo Finance·Mar 26, 2026
- A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion ResultsYahoo Finance·Mar 21, 2026
- Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16Yahoo Finance·Mar 20, 2026
- Sector Update: Health Care Stocks Slip Late AfternoonYahoo Finance·Mar 18, 2026
- CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Mar 18, 2026
- CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study DataYahoo Finance·Mar 17, 2026
- Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer DataMotley Fool·Mar 16, 2026
- CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Mar 16, 2026
All 20 articles loaded
Price Data
Open$4.12
Previous Close$4.08
Day High$4.21
Day Low$4.03
52 Week High$8.21
52 Week Low$0.91
52-Week Range
$0.91$8.21
$4.13
Fundamentals
Market Cap$899M
P/E Ratio—
EPS$-0.15
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-0.2%
Debt / Equity—
Trading
Volume2.6M
Avg Volume (10D)—
Shares Outstanding217.7M
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—